Sage Therapeutics Inc (SAGE) Stock
SAGE is no longer traded. Sage Therapeutics was delisted from the Nasdaq in July 2025.
Prices on this page are historical; the last trade was July 30, 2025 at $8.68.
Sage Therapeutics stock price history
SAGE final trading statistics
- Final close
- $8.68
- Final trading day
- Jul 30, 2025
- Market cap at delisting
- $544.94M
- Shares outstanding
- 62.78M
- Final 52-week range
- $4.62 – $11.44
- Avg. volume (final 3 mo.)
- 2,450,335
- All-time high (split-adj.)
- $192.33 · Feb 2018
- All-time low (split-adj.)
- $4.78 · Nov 2024
- Return since IPO
- -71.2%
- Beta
- 0.30
- Book value / share
- $5.89
- Price / book
- 1.47
Sage Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $41.24M | -$400.7M | -$6.23 |
| FY2023 | $86.45M | -$541.5M | -$10.31 |
| FY2022 | $7.69M | -$503.3M | -$8.98 |
| FY2021 | $6.31M | -$450.8M | -$7.80 |
| FY2020 | $1.11B | $606.1M | $11.64 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. As of July 31, 2025, Sage Therapeutics, Inc. operates as a subsidiary of Saphire, Inc.
Sage Therapeutics stock FAQ
What happened to Sage Therapeutics stock?
Sage Therapeutics stock was delisted from the Nasdaq. Its final close was $8.68 on July 30, 2025.
Is SAGE stock still trading?
No. SAGE was delisted from the Nasdaq in July 2025 and no longer trades on a U.S. exchange.
What was the last price of SAGE stock?
SAGE closed at $8.68 on its final trading day, July 30, 2025, for a market value of about $544.94M.
What were Sage Therapeutics's revenue and earnings in its last full fiscal year?
Sage Therapeutics reported revenue of $41.24M and net income of -$400.7M in fiscal 2024, its last full year as a public company.
When did Sage Therapeutics go public?
Sage Therapeutics Inc stock began trading on July 18, 2014.